B
KURA icon

Bailard’s Kura Oncology KURA Stock Holding History

Bailard’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,434
Closed -$195K – 752
2021
Q3 		$195K Buy
+10,434
New +$197K 0.01% 685
2021
Q2 		– Sell
-81,934
Closed -$2.32M – 730
2021
Q1 		$2.32M Buy
81,934
+42,000
+105% +$1.33M 0.09% 185
2020
Q4 		$1.3M Buy
39,934
+3,100
+8% +$109K 0.06% 189
2020
Q3 		$1.13M Sell
36,834
-9,800
-21% -$216K 0.06% 190
2020
Q2 		$760K Sell
46,634
-1,800
-4% -$26K 0.04% 221
2020
Q1 		$482K Buy
48,434
+6,000
+14% +$68.7K 0.03% 230
2019
Q4 		$583K Buy
42,434
+5,334
+14% +$79K 0.03% 250
2019
Q3 		$563K Sell
37,100
-1,400
-4% -$24.9K 0.03% 251
2019
Q2 		$758K Hold
38,500
– – 0.05% 235
2019
Q1 		$639K Buy
38,500
+8,500
+28% +$131K 0.04% 261
2018
Q4 		$421K Hold
30,000
– – 0.03% 337
2018
Q3 		$525K Hold
30,000
– – 0.03% 362
2018
Q2 		$546K Hold
30,000
– – 0.03% 342
2018
Q1 		$563K Sell
30,000
-3,805
-11% -$74.1K 0.04% 296
2017
Q4 		$517K Buy
+33,805
New +$498K 0.03% 309

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Bailard's KURA Position: Q4 2021 in Review

Bailard sold out of Kura Oncology (KURA) in Q4 2021, closing a stake of 10,434 shares — an estimated $195K sold.

Bailard first reported a position in KURA in Q4 2017 and held it in 15 quarters. The position peaked at $2.32M in Q1 2021. 151 funds tracked by Wall St. Rank hold KURA as of Q4 2021.

  • Bailard reported no remaining Kura Oncology position as of Q4 2021 after selling out during the quarter.
  • Bailard sold 10,434 Kura Oncology shares in Q4 2021, an estimated $195K.
  • Bailard first reported a position in Kura Oncology in Q4 2017 and held it in 15 quarters.
  • Bailard's Kura Oncology position peaked at $2.32M in Q1 2021.
  • 151 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2021.

Based on Bailard's 13F filing for Q4 2021, filed 10 Feb 2022.